HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Rani Therapeutics Holdings (NASDAQ:RANI) and maintained a price target of $13.
June 25, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Rani Therapeutics Holdings (NASDAQ:RANI) and maintained a price target of $13.
The reiteration of a Buy rating and the maintenance of a $13 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to a short-term increase in RANI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100